CHICAGO--(BUSINESS WIRE)--Celsis International plc, the life science products and laboratory services company, today announces the appointment of Philip Vorwald as Vice President and General Manager of its Celsis In Vitro Technologies (Celsis IVT) division. Vorwald brings to Celsis 25 years of experience in the global life science industry. In his new position, Vorwald will be responsible for setting and overseeing the long-term growth strategy of Celsis IVT’s ADME-Tox products. Vorwald will report directly to Celsis’ Chief Executive Officer, Jay LeCoque. “Philip’s extensive life science, international management and business development experience will prove integral in the growth of Celsis IVT,” said Jay LeCoque, CEO of Celsis International plc. “I’m confident that with Phil’s leadership, Celsis IVT will significantly expand its presence in the ADME-Tox drug development market.”
